SLA Center - Purpan University Hospital Toulouse, FRANCE
Toulouse, Occitanie, 31000, France
Location status: Recruiting
NCT Number: NCT05819931
The study aims to evaluate the effect of mechanical insufflator-exsufflator on the respiratory functions of Amyotrophic Lateral Sclerosis (ALS) patients evaluated via peak expiratory flow on cough (PEFC) measurements. The evolution of their PEFC is monitored to see if the curative management can have a positive impact on the latter.
Interested in participating?
Request Info18 year–100 year
All sexes
Interventional
Not applicable
Toulouse, Occitanie, 31000, France
Location status: Recruiting
Amyotrophic Lateral Sclerosis (ALS) is a rare neurodegenerative pathology without curative treatment at present, the outcome is fatal after 3 to 5 years of evolution on average. The disease results in progressive paralysis of the muscles involved in voluntary motricity (progressive and intricate impairment of locomotor, phonation and swallowing capacities as well as ventilatory function). In France, the management of ALS is based on a diversified multidisciplinary follow-up (physiotherapy, speech therapy, occupational therapy, neuropsychology) in the ALS Reference Center in conjunction with the city care networks. It is centered on the evaluation, and the early compensation of the various symptoms, especially the respiratory problems.
Thus, this study aims to evaluate the effect of mechanical insufflator-exsufflator on the respiratory functions of these patients, evaluated via cough peak expiratory flow measurements (CPEF).
The study is conducted in collaboration with the physiotherapists of each patient enrolled, to evaluate the respiratory function by peak expiratory flow on cough (PEFC) after 4 weeks of treatment with Mechanical In-Exsufflator (MIE) (3 weekly sessions for two weeks, then one daily session for 2 weeks) in ALS patients presenting with a poorly effective cough (PEFC between 160 and 255 L/min) and having an indication of punctual MIE.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Exclusion during the study :
The Mechanical In-Exsufflator (MIE) is a device that alternately inhales and exhales air and amplifies the respiratory cycles in flow and pressure. 15 breathing cycles (about 3 minutes) are recommended each day.
Patients will practice the MIE daily independently and/or carried out by his physiotherapist (PT) during PT sessions.
The MIE is prescribed by the neurologist or pulmonologist and is covered by social security in France. It is gifted by an external service provider.
The Peak-Flow Cough is considered as the standardized score retaining the best of 3 consecutive measurements by Peak-Flow, a small portable device for personal use, which measures the maximum expiratory flow reached by the patient at the moment when the breath is most powerful.
The patient is his own control. At baseline, the patient will be treated as usual. He will be asked to read the Peak-Flow Cough measures. The PT will also perform the Peak flow measurement at each patient visit.
Time frame: 4 weeks post treatment initiation
evolution of respiratory function by peak expiratory flow on cough (PEFC) after 4 weeks of treatment with Mechanical In-Exsufflator (3 weekly sessions for two weeks then one daily session for 2 weeks) in ALS patients presenting with a poorly effective cough (Cough Peak Expiratory Flow between 160 and 255) and having an indication of punctual MIE.
Ratio between the PEFC 4 weeks post treatment initiation and PEFC at baseline can show decrease in respiratory function if <1 ; increase in respiratory functions if >1 and a conservation of respiratory function if = 1.
A PEFC remaining within 10% of its initial value (rounded to the nearest ten) is considered unmodified
Contact information is provided by the study sponsor or research team.
Floriane LLORENS
CONTACT
Thierry LAGARDE, PT
CONTACT
University Hospital, Toulouse
Other
Evaluation of the Effect of Respiratory Physiotherapy by Mechanical In-exsufflator on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis: A Pilot Study
Acronym: 2SLA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06581861
Amyotrophic Lateral Sclerosis, Central Nervous System Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT04363684
Amyotrophic Lateral Sclerosis, Basal Ganglia Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT06578195
Amyotrophic Lateral Sclerosis, Central Nervous System Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT06284161
Amyotrophic Lateral Sclerosis, Central Nervous System Diseases
Clermont-Ferrand, France
View Trial Details